Preoperative Combined Radiochemotherapy for Patients With Rectal Carcinoma
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Rate of T-downstaging (Reduction of the T-stadium) at the time of final surgery following the preoperative combined radiochemotherapy (chemotherapy: Oxaliplatin, Capecitabine) Evaluation of the toxicity grade III and IV of the therapy scheme
| Condition | Intervention | Phase |
|---|---|---|
|
Rectal Cancer |
Drug: Capecitabine Drug: Oxaliplatin |
Phase 2 |
| Study Type: | Interventional |
| Study Design: | Allocation: Non-Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Preoperative Combined Radiochemotherapy for Patients With Newly Diagnosed, Primary Operable and Locally Advanced Rectal Carcinoma (cT3, Nx, M0) of the Lower and Middle Rectum |
- Rate of T-downstaging (Reduction of the T-stadium) at the time of final surgery following the preoperative combined radiochemotherapy (chemotherapy: Oxaliplatin, Capecitabine)
- Evaluation of the toxicity grade III and IV of the therapy scheme
| Estimated Enrollment: | 60 |
| Study Start Date: | October 2004 |
| Estimated Study Completion Date: | March 2006 |
About 60 patients with locally advanced rectal carcinoma (cT3, Nx, M0) of the lower and middle rectum will be recruited.
The radiotherapy is an essential part of therapy of the advanced rectal carcinoma and the additional administration of a chemotherapy will positively influence the effect of the therapy (downstaging-rate, rate of distant metastases, survival-rate). Probably a downsizing and downstaging (as per literature and by own experience) can be reached with an preoperative combined radiochemotherapy.
Eligibility| Ages Eligible for Study: | 18 Years to 80 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Age: 18 - 80
- Biooptical confirmed adenocarcinoma of the lower und middle rectum (lower edge of the tumor located max. 14 cm of the anal verge)
- According to MRI tumor extensions into the perirectal fat tissue (cT3)
- No former chemotherapy, radiotherapy and/or tumor resection of a rectum carcinoma
- WHO performance status 0 - 2
- Adequate bone marrow reserve (leucocytes - not more than 3.000/ml; thrombocytes - not more than 100.000/ml)
- Adequate hepatic function (bilirubin - not more than 1.5 x ULN; GOT and GPT - not more than 3.5 x ULN)
- Adequate renal function (creatinin - not more than 1.5 mg/dl)
- Women of childbearing potential: exclusion of pregnancy (negative urin or serum pregnancy test)
- Willingness of women of childbearing potential and accordingly of potent men to use approved contraceptives (for example birth-control pill, loop, condom) during and at least 3 month after closure of the study
- Life expectancy of at least 3 month
- Signed written Informed Consent before recruitment
- Exclusion of distant metastases at the time of recruitment
Exclusion Criteria:
- Former radio- and/or chemotherapy
- Tumor of the upper rectum
- Any other kind of malign tumor in the last five years (except adequate treated basal cell carcinoma of the skin, or in situ cervical carcinoma)
- Peripheral Neuropathy (NCI CTC - not higher than Grade 1)
- General contraindication or hypersensitivity against Oxaliplatin and/or Capecitabine
- Any other untreated not malign diseases: Cardiac insufficiency, angina pectoris, hypertension or arrhythmia, hepatic diseases, significant neurological or psychiatric disorders
- Florid, serious infection at the time of recruitment
- Legally limited capacity or evidence of a neurological or psychiatric disease, the investigator is the opinion it will constrict the patients compliance
- Evidence of lacking willingness for cooperation of the patient
- Pregnant or breast feeding women
Contacts and Locations| Austria | |
| Hospital BHB St. Veit/Glan, Surgery | |
| St. Veit a. d. Glan, Carinthia, Austria, 9330 | |
| Hospital Wiener Neustadt | |
| Wiener Neustadt, Lower Austria, Austria, 2700 | |
| Medical University of Graz, Oncology | |
| Graz, Styria, Austria, 8036 | |
| State Hospital Leoben, Surgery | |
| Leoben, Styria, Austria, 8700 | |
| Medical University of Innsbruck, Surgery | |
| Innsbruck, Tyrol, Austria, 6020 | |
| Hospital BHS Linz | |
| Linz, Upper Austria, Austria, 4020 | |
| Hospital Kreuzschwestern Wels | |
| Wels, Upper Austria, Austria, 4600 | |
| State Hospital, Radiooncology | |
| Feldkirch, Vorarlberg, Austria, 6807 | |
| Paracelsus Medical University Salzburg - Oncology | |
| Salzburg, Austria, 5020 | |
| Medical University of Vienna, Radiotherapy | |
| Vienna, Austria, 1090 | |
| Principal Investigator: | Dietmar Oefner, MD | Austrian Breast & Colorectal Cancer Study Group |
| Principal Investigator: | Alexander de Vries, MD | Austrian Breast & Colorectal Cancer Study Group |
| Principal Investigator: | Josef Thaler, MD | Austrian Breast & Colorectal Cancer Study Group |
More Information
Additional Information:
No publications provided by Austrian Breast & Colorectal Cancer Study Group
Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| ClinicalTrials.gov Identifier: | NCT00297141 History of Changes |
| Other Study ID Numbers: | ABCSG 95 / TAKO 05, Studie 95, EudraCT: 2004-002358-72 |
| Study First Received: | February 27, 2006 |
| Last Updated: | January 19, 2007 |
| Health Authority: | Austria: Federal Ministry for Health and Women |
Keywords provided by Austrian Breast & Colorectal Cancer Study Group:
|
Preoperative Radiochemotherapy Newly Diagnosed Primary Operable Locally Advanced Rectal Carcinoma T3 |
Lower Rectum Middle Rectum ABCSG TAKO 95 05 |
Additional relevant MeSH terms:
|
Carcinoma Rectal Neoplasms Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Neoplasms Colorectal Neoplasms Intestinal Neoplasms Gastrointestinal Neoplasms Digestive System Neoplasms Neoplasms by Site Digestive System Diseases |
Gastrointestinal Diseases Intestinal Diseases Rectal Diseases Oxaliplatin Capecitabine Antineoplastic Agents Therapeutic Uses Pharmacologic Actions Antimetabolites, Antineoplastic Antimetabolites Molecular Mechanisms of Pharmacological Action |
ClinicalTrials.gov processed this record on May 19, 2013